NEO
Overvalued by 230.1% based on the discounted cash flow analysis.
Market cap | $184.81 Million |
---|---|
Enterprise Value | $380.46 Million |
Dividend Yield | $0 (0%) |
Earnings per Share | $-3.1 |
Beta | 1.64 |
Outstanding Shares | 25,475,200 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -2.36 |
---|---|
PEG | 56.06 |
Price to Sales | 0.28 |
Price to Book Ratio | 0.22 |
Enterprise Value to Revenue | 0.57 |
Enterprise Value to EBIT | -3.88 |
Enterprise Value to Net Income | -5 |
Total Debt to Enterprise | 1.42 |
Debt to Equity | 0.61 |
No data
No data
NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The ...